| Tracey Outman, MS CCC-SLP | |
|
932 E Baddour Pkwy, Lebanon, TN 37087-3700 | |
| (615) 496-4914 | |
| Not Available |
| Full Name | Tracey Outman |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 932 E Baddour Pkwy, Lebanon, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043913718 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1340 (Tennessee) | Primary |
| Provider Name | Functional Pathways Preferred Of Tennessee Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1841561446 PECOS PAC ID: 2860649654 Enrollment ID: O20121228000137 |
News Archive
UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
Interluekin-1α (IL-1α) is an important part of the immune response, but until now it has been unclear how this molecule is processed from its precursor, pro-IL-1α, and exits the cell during inflammasome activation.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tracey Outman, MS CCC-SLP 5551 W Shady Trl, Old Hickory, TN 37138-1319 Ph: (615) 496-4914 | Tracey Outman, MS CCC-SLP 932 E Baddour Pkwy, Lebanon, TN 37087-3700 Ph: (615) 496-4914 |
News Archive
UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.
Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
Interluekin-1α (IL-1α) is an important part of the immune response, but until now it has been unclear how this molecule is processed from its precursor, pro-IL-1α, and exits the cell during inflammasome activation.
› Verified 2 days ago
Krista Bright, SLP/CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 351 Stumpy Ln, Lebanon, TN 37090 Phone: 423-622-1551 Fax: 877-665-5586 | |
Lauren Crotzer, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6285 Se Tater Peeler Rd, Lebanon, TN 37090 Phone: 615-584-8284 | |
Damaris Wilson, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 397 N Castle Heights Ave, Lebanon, TN 37087 Phone: 423-622-1551 | |
Susan Victoria Graham, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 351 Stumpy Ln, Lebanon, TN 37090 Phone: 615-443-4445 Fax: 615-443-4448 | |
Nancy Turner-jones, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 351 Stumpy Ln, Lebanon, TN 37090 Phone: 423-622-1551 Fax: 423-622-1556 | |
Carson Morris, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 163 Business Park Dr Ste 11, Lebanon, TN 37090 Phone: 812-239-8368 |